The Next Generation Biotech Media
On January 19th, Verve Therapeutics announced it raised $94 million in investments as part of a Series B financing. The money will be used to advance the company’s gene-editing therapies, …
Read More
Thermo Fisher Scientific seems to be in the mood for acquiring COVID-19 related testing tools and is spending hundreds of millions on acquiring small to large-sized companies. The latest in …
Read More
On January 4th, China-based biotech Gracell Biotechnologies (Gracell) revealed details of the IPO. Gracell is offering 8.8 million American depositary shares (ADS) with 16 to 18 apiece, which will result …
Read More
Aro Biotherapeutics, which specializes in the development of tissue-targeted genetic medicines, announced on January 5th that it has managed to secure $88 million in Series A financing from several venture …
Read More
The new year has brought good news for Boston-based Ikena oncology, which raised $120 million to push its pipeline of patient-specific, next-generation targeted oncology and immunometabolism therapies. This funding comes …
Read More
What’s a SPAC? Special Purpose Acquisition Companies have become more popular in recent years despite being around for decades. The company has no commercial operations and is formed strictly to …
Read More
Unlike 2019, when two heavy-hitting pharma acquisition deals illuminated the J.P. Morgan Healthcare Conference, the 2020 event stood in stark contrast featuring none. With the uncertainty surrounding the drug pricing …
Read More
On December 21st, Servier announced that it would acquire Agios Pharmaceuticals for up to $2 billion. This acquisition will give Servier two FDA approved therapeutics, TIBSOVO, and IDHIFA, as well …
Read More
Cambridge, MA-based Cadent Therapeutics is a privately-held clinical-stage biopharmaceutical company that develops therapies for the treatment of cognitive, mood, and movement disorders with a focus on small molecules targeting neuronal …
Read More
On December 14th, Locanabio announced it had raised $100 million in a Series B financing. The funding will be used to advance the pre-clinical and clinical development of their CRISPR-mediated …
Read More